Evaxion Biotech A/S
EVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $54,157 | $40,894 | $90,766 |
| - Cash | $10,572 | $14,746 | $17,843 | $5,052 |
| + Debt | $0 | $11,283 | $0 | $10,101 |
| Enterprise Value | – | $50,694 | $23,051 | $95,815 |
| Revenue | $7,492 | $37 | $0 | $122 |
| % Growth | 20,148.6% | – | -100% | – |
| Gross Profit | $7,492 | $37 | $0 | $122 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | $5,712 | -$4,785 | -$1,375 | -$5,516 |
| % Margin | 76.2% | -12,932.4% | – | -4,521.5% |
| Net Income | $4,618 | -$4,831 | -$1,580 | -$3,629 |
| % Margin | 61.6% | -13,056.8% | – | -2,974.6% |
| EPS Diluted | 4.2 | -4.4 | -0.5 | -3.4 |
| % Growth | 195.5% | -780% | 85.3% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |